Registered title, quoted from ClinicalTrials.gov
HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Renji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07045558, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Confirmed unresectable hepatocellular carcinoma (BCLC stage B/C) by histology, cytology, or clinical diagnosis.
Inclusion criterion 2
Child-Pugh class A or B7.
Inclusion criterion 4
No prior systemic therapy received, with an expected survival ≥12 weeks.
Inclusion criterion 6
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
Inclusion criterion 5
At least one measurable lesion based on RECIST version 1.1.
Inclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07045558, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients between 18 and 75 years old, with no gender restrictions.
- Confirmed unresectable hepatocellular carcinoma (BCLC stage B/C) by histology, cytology, or clinical diagnosis.
- At least one measurable lesion based on RECIST version 1.1.
- Child-Pugh class A or B7.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
- No prior systemic therapy received, with an expected survival ≥12 weeks.
- Adequate organ function meeting the following criteria:
A. Hematological parameters (without blood transfusion within 14 days): Hemoglobin (Hb) ≥80 g/L, White blood cell count (WBC) ≥3 × 10⁹/L, Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, Platelet count (PLT) ≥50 × 10⁹/L; B. Biochemical parameters: Total bilirubin (TBIL) <1.5 × upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5 × ULN, Serum creatinine (Cr) ≤1.5 × ULN.
- Contraception requirements: Women of childbearing age must have a negative serum or urine pregnancy test (HCG) within 7 days before enrollment and agree to use effective contraceptive methods during the trial period and for 8 weeks after the last dose. Men must either have undergone surgical sterilization or agree to use appropriate contraceptive methods during the trial period and for 8 weeks after the last dose.
- Willingness to voluntarily participate in the study, with good compliance and commitment to follow-up.
Exclusion Criteria:
- Known intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma, sarcomatoid HCC, or fibrolamellar carcinoma.
- Concurrent autoimmune diseases, organ/hematopoietic stem cell transplantation history, or other malignancies.
- Impaired consciousness, inability to cooperate with treatment, or active psychiatric disorders.
- Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), bevacizumab, molecular targeted therapy, atezolizumab, or other PD-1/PD-L1 inhibitors received before enrollment.
- Major surgery, chemotherapy, radiotherapy, or systemic therapy for lesions received within 1 month before enrollment.
- Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone or other equivalent drugs) within 14 days before enrollment.
- Severe esophageal varices or high risk of bleeding assessed by endoscopy.
- Evidence of decompensated liver function, including ascites, gastrointestinal bleeding, or hepatic encephalopathy.
- Severe organ dysfunction in major organs such as the liver, kidneys, heart, lungs, or brain.
- Other contraindications for interventional therapy, molecular targeted therapy, or immunotherapy.
- Inability to undergo scheduled follow-up or concurrent participation in other clinical trials that may interfere with this study.
- Other severe comorbidities deemed by the investigator to jeopardize patient safety or compromise study completion.
Quoted from ClinicalTrials.gov, NCT07045558, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07045558, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.